Loading market dashboard
ANI Pharmaceuticals, Inc.
ANIPHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows:
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.7 per share a year ago.
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.
ANI Pharmaceuticals rides Cortrophin Gel's surge to anchor 2026 growth, with rising guidance and new initiatives positioning the specialty portfolio for continued momentum.
ANI Pharmaceuticals trades at 10x forward earnings with a $93 target, but execution in Cortrophin and ophthalmology recovery may decide if the discount closes.
ANIP eyes 2026 growth via Cortrophin's gout push and steady generics launches, as Rare Disease expansion reshapes priorities and investor focus.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®.
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The consensus price target hints at a 41.7% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
SUBCY, MKSI, ANIP, AHKSY and ADSK have been added to the Zacks Rank #1 (Strong Buy) List on April 16, 2026.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Monday, April 13th. The shares were sold at an average price of $77.95, for a total transaction of $38,975.00. Following the transaction, the vice president directly owned 78,890 shares of the company's stock,
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®.
ANI Pharmaceuticals continues shifting toward rare diseases, with management projecting that this segment will represent 60% of its 2026 revenues. However, their generics remain a reliable cash engine. These products grew 28% in 2025 and reached $384 million in revenues. This way, ANIP has been able to fund its expansion into rare diseases, with Cortrophin as its flagship asset in this category.
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI's Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®.
INTU, ANIP and GLPI stand out this April as earnings acceleration signals potential stock gains before broader market recognition kicks in.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
ANI Pharmaceuticals recently offered up solid FY26 guidance with 15% non-GAAP EPS growth and strong momentum from Cortrophin Gel. ANIP's increasing reliance on Cortrophin Gel, projected to reach 52% of FY26 revenue, is offset by patent protection and a complex formulation. The company's balance sheet remains solid, supporting ongoing investments in rare disease expansion and 10–15 annual generic launches.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The mean of analysts' price targets for ANI (ANIP) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
ANI Pharmaceuticals ANIP has shifted into a specialty-led growth story, with Cortrophin Gel now the main engine and the retina franchise positioned for a reset and recovery. At the same time, the stock's valuation has compressed to levels that stand out against peers and the broader market.
ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio reset.
An executive at ANI Pharmaceuticals reported the sale of 4,772 shares on March 11, 2026 for a transaction value of $357,000, at a reported price of $74.91 per share. This sale represented 10.97% of Rowland Thomas Andrew's direct common stock holdings, reducing direct ownership to 38,730 shares post-transaction.
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average
Apis Capital Advisors LLC raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 28.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 164,000 shares of the specialty pharmaceutical company's stock after buying an additional 36,000 shares
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
The mean of analysts' price targets for ANI (ANIP) points to a 44.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals (NASDAQ: ANIP) executives used a presentation at the Leerink Partners Global Healthcare Conference to outline the company's recent performance, 2026 financial outlook, and commercial initiatives centered on its rare disease portfolio, led by Cortrophin Gel. 2025 results and 2026 guidance Chief Executive Officer Nikhil Lalwani described ANI as a "high-growth biopharmaceutical company" that is
ANI (ANIP) possesses solid growth attributes, which could help it handily outperform the market.
